Company / Named in our posts
Atreca, Inc..
Follow Atreca, Inc.Atreca had preclinical monoclonal-antibody assets in oncology and platform-related assets.[1]
01Deal
Deals on Carrywatch
Every deal that names Atreca, Inc., and its role in each.
Immunome, Inc. / Atreca, Inc.
Immunome, Inc. agrees to buy Atreca, Inc.
See deal detailsDeal Web
Atreca, Inc. and 0 firms it shares a posted deal with, and the path to any other firm.
Financials
4 fiscal years of figures as Atreca, Inc. reported them.
News
Loading headlines.
Sources
As of 24 Oct 2026.
- 01Atreca, Inc. Form 8-K
U.S. Securities and Exchange Commission · Researched 24 Oct 2026
- 02SEC EDGAR company record for Atreca, Inc. (CIK 0001532346)
U.S. Securities and Exchange Commission · Researched 24 Oct 2026
Deal posts naming Atreca, Inc.:
- P01Atreca, Inc.: Immunome, Inc. / Atreca, Inc.
26 Dec 2023